CardioVascular BioTherapeutics

CardioVascular BioTherapeutics, Inc. (OTC/BB: CVBT) is a biopharmaceutical company focused on developing protein drug candidates to be used in the treatment of cardiovascular disease, the worldwide leading cause of death. The Company is developing injectable and topical formulations of its active pharmacological ingredient (API) to facilitate the growth of new blood vessels (angiogenesis) in the heart, tissues and organs that have been compromised by impaired blood supply (hypoxia, ischemia). The Company’s API contains FGF-1141 a human protein manufactured using a proprietary technology. FGF-1 stimulates the growth and proliferation of the three main cell types of blood vessels; endothelial cells, smooth muscles cells and pericytes. CVBT-141A, the Company’s lead drug candidate successfully completed initial clinical trials in Germany during the 1990s, with no drug-related adverse events and a statistically significant increase in localized blood vessel growth (and perfusion) both in patients also receiving coronary by-pass procedures and in patients with severe coronary heat disease (CHD) receiving CVBT-141A, as the sole therapy. Enrollment and treatment has been completed in an FDA authorized Phase I study with CVBT-141A, administered via injection in severe CHD patients. The protocol design for the Phase II trial is underway, with FDA input, and is planned to initiate in 2007. CardioVascular BioTherapeutics, Inc. is committed to conducting additional clinical trials to establish the positive effect of FGF-1141 aimed at improving the quality of life for those suffering from heart disease, stroke, diabetic wounds, or peripheral artery disease, and pledges to continue exploration for additional applications of FGF-1.

Contact Details: 1635 Village Center Circle Suite 250 Las Vegas NV 89134 United States of America Tel: (702) 248-1174 Fax: Email: WWW: www.cvbt.com/

Loading...

Recent Publications by CardioVascular BioTherapeutics:
Combating cardiovascular disease with angiogenic therapy. For over a decade we have lived with the promise that therapeutic...	8th March, 2008	CardioVascular BioTherapeutics, Inc., 1635 Village Center Circle, Las	Drug Discov Today. 2007 Dec;12(23-24):1040-5. Epub 2007 Oct 18. DOI Direct Link

Press Releases on CardioVascular BioTherapeutics:
CVBT Opens Florida and Arizona Sites for Its ACORD Phase II Heart Trial	24th February, 2009	CardioVascular BioTherapeutics, Inc.	LAS VEGAS, Feb. 24 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) announced today that two additional hospitals in the United States opened for patient
CVBT Opens Two Additional Sites for Its ACORD Phase II Heart Trial	8th January, 2009	CardioVascular BioTherapeutics, Inc.	LAS VEGAS, Jan. 8 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) announced today that two additional hospitals in the United States opened for patient
CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial	9th September, 2008	CardioVascular BioTherapeutics, Inc.	LAS VEGAS, Sept. 9 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) today announces that its first US site is open for patient enrollment for its Phase II

BioNews Results for CardioVascular BioTherapeutics:
CNS Protein Therapeutics Completes Name Change to Amarantus Therapeutics, Appoints New CEO Martin D. Cleary	Pharma Live:  Oct 30 2009 10:55PM Matching: cardiovascular biotherapeutics
CNS Protein Therapeutics Renamed as Amarantus Therapeutics, Appoints Juvaris Founder as CEO	Pharma Live:  Oct 30 2009 6:13PM Matching: cardiovascular biotherapeutics
Cardium's Gene Activated Matrix technology Accelerates Periodontal Tissue Regeneration	Pharmaceutical Business Review:  Sep 16 2009 9:12AM Matching: cardiovascular biotherapeutics
Daiichi Sankyo, Ranbaxy Launch Evista In Romania	Pharmaceutical Business Review:  Sep 2 2009 12:44AM Matching: cardiovascular biotherapeutics

CardioVascular BioTherapeutics Clinical Trials:
Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease

CardioVascular BioTherapeutics (CVBT.OB) Financial information Links from Barchart
CVBT.OB Quote from from Barchart.com
CVBT.OB Chart from from Barchart.com
CVBT.OB Profile from from Barchart.com
CVBT.OB Opinion from from Barchart.com
→View more CardioVascular BioTherapeutics finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 523 times since April 2007, the link to the organisation's website has been followed 125 times

Search for more companies in Las Vegas

Search for more companies in NV

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for CardioVascular BioTherapeutics